Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Input metadata referenced "ARTIVION, INC." but the filing text identifies the registrant as CryoLife, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: CryoLife operates in two primary segments: Human Tissue Preservation Services (cryopreservation of cardiac, vascular, and orthopaedic tissues) and Implantable Medical Devices (BioGlue and bioprosthetic devices). The company is currently transitioning its orthopaedic tissue business to Regeneration Technologies, Inc. (RTI) under an exchange agreement while expanding its cardiovascular and vascular tissue operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Three Months Ended June 30, 2006 |
Six Months Ended June 30, 2007 |
Six Months Ended June 30, 2006 |
|---|---|---|---|---|
| Total Revenues | $23,011 | $20,754 | $47,535 | $40,203 |
| Net Income (Loss) | $1,291 | $217 | $2,645 | $(1,563) |
| Net Income Applicable to Common Shares | $1,291 | $(27) | $2,402 | $(2,050) |
| Diluted EPS | $0.05 | $0.00 | $0.09 | $(0.08) |
| Operating Cash Flow (6mo) | $1,426 (2007) vs. $(3,898) (2006) | |||
| Cash & Equivalents (Balance Sheet) | $5,519 (June 30, 2007) | |||
| Debt (Line of Credit) | $4,501 Outstanding; $10.0M Availability |
Segment Performance (Six Months Ended June 30, 2007)
- Human Tissue Preservation Services: Revenue of $24.7M (up 26% YoY). Driven by cardiovascular (+36%) and vascular (+35%) growth, offset by orthopaedic declines (-13%).
- Implantable Medical Devices: Revenue of $22.6M (up 9% YoY). Primarily driven by BioGlue sales (+10%).
- Gross Margin: Total gross margin was $29.1M, representing a 61% gross margin rate.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11% for the quarter and 18% for the six-month period compared to 2006. This was driven by price increases (effective July 2006 and January 2007) and volume growth in cardiovascular/vascular tissues and BioGlue.
- Profitability Turnaround: The company returned to profitability, reporting net income of $2.6M for the six months ended June 30, 2007, compared to a net loss of $1.6M in the same period in 2006.
- Derivative Expense: A significant non-cash expense of $821,000 was recorded for the six months ended June 30, 2007, related to the revaluation and settlement of the "Dividend Make-Whole" derivative liability upon the automatic conversion of preferred stock. This contrasts with only $67,000 in the prior year period.
- Orthopaedic Decline: Orthopaedic tissue revenues decreased 33% in the quarter and 13% for the six months due to the cessation of new orthopaedic tissue procurement under the RTI Agreement.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes existing cash, marketable securities, and credit facility availability ($10.0M remaining) are sufficient to meet liquidity needs through at least June 30, 2008.
- Revenue Drivers: Anticipated revenue growth for the remainder of 2007 is expected from BioGlue price increases, volume growth in cardiovascular/vascular tissues, and fee increases for preservation services.
- Orthopaedic Transition: Orthopaedic revenues are expected to decline significantly as existing inventory is depleted. The company expects to transition to distributing RTI's cardiovascular/vascular inventory after June 30, 2008.
Risks and Contingencies
- Product Liability: An actuarial estimate as of June 30, 2007, placed the liability for unreported product liability claims at $5.9 million (with a potential range up to $11.4 million). The company has recorded a $2.1 million receivable for insurance recoveries. One pending lawsuit regarding allograft heart valve tissue is in the discovery stage.
- Regulatory (FDA): The FDA has questioned the adequacy of the company's response to a 2005 Form 483 notice. Additionally, the company is awaiting FDA clearance for SynerGraft processed tissues (CryoValve SG and CryoVein SG), which are currently suspended from distribution pending regulatory approval.
- SEC Investigation: The company is subject to an ongoing SEC investigation regarding potential insider trading and disclosure practices related to 2002 events. The outcome remains uncertain.
- Debt Covenants: The company must maintain specific EBITDA and BioGlue gross margin levels (70%) to maintain borrowing availability under its credit agreement.
Investor Verification Checklist
- Product Liability Exposure: Verify the adequacy of the $5.9M accrual for unreported claims and the likelihood of insurance recoveries covering the full liability.
- Orthopaedic Run-rate: Assess the timeline for the depletion of orthopaedic inventory and the potential revenue gap before RTI's cardiovascular inventory becomes fully available.
- FDA Status: Monitor the status of the SynerGraft regulatory submissions and the resolution of the Form 483 observations, as these impact future product lines.
- Preferred Stock Conversion: Confirm the impact of the June 2007 automatic conversion of preferred stock on future earnings per share (elimination of preferred dividends).
- SEC Investigation: Track any updates regarding the scope or potential penalties of the ongoing SEC investigation.